Sign in
Taking peoplePhase 2

Sacituzumab tirumotecan for thymic carcinoma that returned after platinum chemotherapy

Tests sacituzumab tirumotecan in adults whose thymic carcinoma progressed after platinum-based chemotherapy.

Key facts

Who runs it
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
Status
Recruiting
Phase
Phase 2
People taking part
30 people, planned
Started
13 Mar 2026
Expected to end
Oct 2028
Type of study
Interventional
Treatments tested
  • Sacituzumab tirumotecan
Record updated
12 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with thymic carcinoma that has spread locally or to other parts of the body. Their cancer must have grown after platinum-based chemotherapy.

Age
18 to 75 years
Sex
All sexes can join.
Disease stage
Locally advanced or metastatic thymic carcinoma, confirmed by tissue or cell tests. Treatment meant to remove all of the disease is not an option. At least one measurable tumor not treated with radiotherapy (RECIST v1.1). ECOG performance status 0 or 1, meaning fully active or only mildly limited. Expected survival of at least 12 weeks.
Earlier treatment
The cancer must have grown after at least one platinum-based chemotherapy.
Biomarker or test result
A tumor tissue sample must be available, taken at or after the diagnosis of advanced disease.

Main reasons for not taking part

  • Thymoma or thymic neuroendocrine tumor
  • Cancer spread to the brain lining, brainstem or spinal cord, or active or untreated brain metastases
  • Another cancer within 3 years before the first dose
  • Past lung inflammation (interstitial lung disease or pneumonitis) that needed steroids, or severe lung problems
  • Active hepatitis B, hepatitis C or tuberculosis

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Males or females aged ≥ 18 to ≤ 75 years at the time of signing the Informed Consent Form
  • Participants with histologically or cytologically confirmed thymic carcinoma, and locally advanced or metastatic thymic carcinoma who are not suitable for curative intent therapy
  • Participants with advanced thymic carcinoma who have progressed after at least one prior platinum-based chemotherapy
  • Able to provide a tumor tissue sample at the time of or after the diagnosis of locally advanced or metastatic tumor
  • At least one measurable target lesion that has not received radiotherapy according to RECIST v1.1
  • ECOG performance status score of 0 or 1
  • Expected survival ≥ 12 weeks
  • Adequate organ and bone marrow function

Who cannot take part

  • Participants with other malignant tumors within 3 years prior to the first dose
  • Presence of any of conditions or risk factors related to cardiovascular and cerebrovascular diseases
  • Uncontrolled systemic disease as judged by the investigator
  • History of interstitial lung disease/noninfectious pneumonitis requiring steroid therapy
  • Clinically severe pulmonary impairment due to lung disorder
  • Presence of active hepatitis B or hepatitis C
  • Known active tuberculosis
  • Known hypersensitivity to the study drug or any of its components
  • Participants with histologically or cytologically confirmed thymoma or thymic neuroendocrine tumor
  • Participants with known metastases to meninges, brainstem metastases, spinal cord metastases and/or compression, active or untreated brain metastases

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if drug Sac-TMT works to treat Thymic Carcinoma. It will also learn about the safety of Sac-TMT. The main questions it aims to answer are:

Read full original descriptionShow less

* How effective is drug Sac-TMT in treating Thymic Carcinoma? * What adverse events (AEs) do participants have when taking drug Sac-TMT?

Participants will:

* Progress after at least one platinum-based chemotherapy treatment. * Take drug Sac-TMT every 2 weeks. * Take tumor response assessments every 6 weeks.

The group in the trial

  • Sac-TMT 5mg/kg Q2WTreatment being tested

    Treatment: Sacituzumab tirumotecan

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase II Clinical Study of Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma With Treatment Failure After Platinum-Based Therapy
Plain-language title
Sacituzumab tirumotecan for thymic carcinoma that returned after platinum chemotherapyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07324629, who can take part
Record updated
12 August 2026